Since type II interferon can also induce IRF1, and this cytokine was FDA-approved for other indications, future studies should examine the effects of type II IFN on melanomas that are IRF2-deficient and its potential as an adjuvant therapy with CPI. The gene discussed is IRF2; the disease is melanoma.